← Leaderboards
Sean Adam Wasserman
University Of Cape Town
$2,761,994
Attributed
$5,120,312
Total exposure
2
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.3M · FY2019–25$2M$1.5M$1M$500K$0
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$5,120,312 · 2
By mechanism
U01$4,716,636 · 1
K43$403,676 · 1
Top collaborators
- Serena Patricia Koenig6 shared
Most similar at University Of Cape Town
Same institution · by research overlap
- Helen McIlleron$2,642,748
- Robert John Wilkinson$5,301,802
- Muazzam Jacobs$336,549
Others in their field
Other Emerging Leaders on “Safety”
- Beth Baseler · Leidos Biomedical Research, Inc.$225,257,316
- Kimberly Smith · Ppd Development Lp$122,008,792
- Klaus Romero · Critical Path Institute$90,404,592
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$75,904,237
- Yunda Huang · Fred Hutchinson Cancer Center$70,809,823
- Leonard Freedman · Leidos Biomedical Research, Inc.$64,938,611
Research focus
SafetyRegimenPharmaceutical PreparationsRifampinSouth AfricaAdultEfficacy TrialFutureRandomizedResponseDoseDrug InteractionsTuberculosisTuberculosis DrugsDesignDrug-SensitiveEvaluationClinical PracticePre-ClinicalClinical TrialsDrug KineticsArtificial IntelligenceAdverse Event MonitoringDrug Exposure
Grant awards (10)
PRESCIENT: A phase IIc, open-label, randomized controlled trial of ultra-short course bedaquiline, clofazimine, pyrazinamide and delamanid versus standard therapy for drug-susceptible tuberculosis$406,451
U01 · FY2025 · AI
PRESCIENT: A phase IIc, open-label, randomized controlled trial of ultra-short course bedaquiline, clofazimine, pyrazinamide and delamanid versus standard therapy for drug-susceptible tuberculosis$398,334
U01 · FY2025 · AI
PRESCIENT: A phase IIc, open-label, randomized controlled trial of ultra-short course bedaquiline, clofazimine, pyrazinamide and delamanid versus standard therapy for drug-susceptible tuberculosis$366,165
U01 · FY2025 · AI
PRESCIENT: A phase IIc, open-label, randomized controlled trial of ultra-short course bedaquiline, clofazimine, pyrazinamide and delamanid versus standard therapy for drug-susceptible tuberculosis$1,143,959
U01 · FY2024 · AI
PRESCIENT: A phase IIc, open-label, randomized controlled trial of ultra-short course bedaquiline, clofazimine, pyrazinamide and delamanid versus standard therapy for drug-susceptible tuberculosis$1,180,713
U01 · FY2023 · AI
PRESCIENT: A phase IIc, open-label, randomized controlled trial of ultra-short course bedaquiline, clofazimine, pyrazinamide and delamanid versus standard therapy for drug-susceptible tuberculosis$1,221,014
U01 · FY2022 · AI
Characterizing the pharmacokinetics of high dose rifampicin and linezolid in a randomized controlled trial for HIV-associated tuberculous meningitis$107,813
K43 · FY2022 · TW · contact PI
Characterizing the pharmacokinetics of high dose rifampicin and linezolid in a randomized controlled trial for HIV-associated tuberculous meningitis$103,369
K43 · FY2021 · TW · contact PI
Characterizing the pharmacokinetics of high dose rifampicin and linezolid in a randomized controlled trial for HIV-associated tuberculous meningitis$98,644
K43 · FY2020 · TW · contact PI
Characterizing the pharmacokinetics of high dose rifampicin and linezolid in a randomized controlled trial for HIV-associated tuberculous meningitis$93,850
K43 · FY2019 · TW · contact PI